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The burden of neurological diseases in Europe: an analysis 
for the Global Burden of Disease Study 2017
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Summary
Background Neurological disorders account for a large and increasing health burden worldwide, as shown in the 
Global Burden of Diseases (GBD) Study 2016. Unpacking how this burden varies regionally and nationally is 
important to inform public health policy and prevention strategies. The population in the EU is older than that of the 
WHO European region (western, central, and eastern Europe) and even older than the global population, suggesting 
that it might be particularly vulnerable to an increasing burden of age-related neurological disorders. We aimed to 
compare the burden of neurological disorders in the EU between 1990 and 2017 with those of the WHO European 
region and worldwide.
Methods The burden of neurological disorders was calculated for the year 2017 as incidence, prevalence, mortality, 
disability-adjusted life-years (DALYs), years of life lost, and years lived with disability for the countries in the EU and 
the WHO European region, totally and, separately. Diseases analysed were Alzheimer’s disease and other dementias, 
epilepsy, headache (migraine and tension-type headache), multiple sclerosis, Parkinson’s disease, brain cancer, motor 
neuron diseases, neuroinfectious diseases, and stroke. Data are presented as totals and by sex, age, year, location and 
socio-demographic context, and shown as counts and rates.
Findings In 2017, the total number of DALYs attributable to neurological disorders was 21·0 million (95% uncertainty 
interval 18·5–23·9) in the EU and 41·1 million (36·7–45·9) in the WHO European region, and the total number of 
deaths was 1·1 million (1·09–1·14) in the EU and 1·97 million (1·95–2·01) in the WHO European region. In the EU, 
neurological disorders ranked third after cardiovascular diseases and cancers representing 13·3% (10·3–17·1) of total 
DALYs and 19·5% (18·0–21·3) of total deaths. Stroke, dementias, and headache were the three commonest causes of 
DALYs in the EU. Stroke was also the leading cause of DALYs in the WHO European region. During the study period 
we found a substantial increase in the all-age burden of neurodegenerative diseases, despite a substantial decrease in 
the rates of stroke and infections. The burden of neurological disorders in Europe was higher in men than in women, 
peaked in individuals aged 80–84 years, and varied substantially with WHO European region and country. All-age 
DALYs, deaths, and prevalence of neurological disorders increased in all-age measures, but decreased when using 
age-standardised measures in all but three countries (Azerbaijan, Turkmenistan, and Uzbekistan). The decrease was 
mostly attributed to the reduction of premature mortality despite an overall increase in the number of DALYs.
Interpretation Neurological disorders are the third most common cause of disability and premature death in the EU 
and their prevalence and burden will likely increase with the progressive ageing of the European population. Greater 
attention to neurological diseases must be paid by health authorities for prevention and care. The data presented here 
suggest different priorities for health service development and resource allocation in different countries.
Funding European Academy of Neurology.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Neurological disorders are an important source of 
premature mortality and transient or permanent disa­
bility in survivors. According to WHO, in 2006, neuro­
logical disorders were identified as one of the greatest 
public health problems, accounting for 6·3% of total 
disability­adjusted life­years (DALYs).1 A report by the 
Global Burden of Disease (GBD) 2015 Neurological 
Disorders Collaborator Group2 estimated that neuro­
logical disorders have become a leading cause of 
disability in the world, with attributable DALYs 
reaching 11·6%, and ranked second in terms of deaths 
after cardiovascular diseases, reaching 16·5% of all 
deaths.2 Given that the prevalence of most neurological 
disorders increases with age, their burden is expected 
to rise in countries with with ageing populations. In 
Europe, the population is rapidly ageing, therefore, this 
region is an important setting for the assessment of 
the dynamics of the burden of neurological disorders. 
Some European countries continue to strengthen their 
cooperation around health strategy and so knowledge 
about the similarities and disparities in the burden of 
neurological diseases across European countries could 
inform political decision making.
We aimed to calculate incidence, prevalence, mortality, 
DALYs, and their components (years of life lost [YLLs], 
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and years lived with disability [YLDs]) as absolute numbers 
and rates attributable to neurological disorders in the 
so­called EU28 (the 27 member countries of the EU plus 
the UK), in general and by age, sex, year, and location for 
the period 1990–2017, and to compare the EU28 with the 
WHO Europe region and the rest of the world.
Methods
Overview
The GBD Collaborator Group is a network of scientists 
producing estimates of the burden of 328 diseases 
and injuries including 13 neurological disorders 
(stroke, Alzheimer’s disease and other dementias, 
Parkinson’s disease, epilepsy, multiple sclerosis, brain 
and nervous system cancer, encephalitis, meningitis, 
tetanus, head ache [migraine and tension­type headache], 
motor neuron diseases, and other neurological diseases). 
The guiding principle of GBD is to assess health loss due 
to premature mortality and disability, intended as 
any deviation from full health. The methodological basis 
of the GDB studies is described in detail elsewhere.2–4
The analyses in the current study follow the GBD 
methodology. The data provided here are for 1990–2017. 
Population­based measures are taken from the related 
GBD standards.5 For the purposes of this study, data on 
GBD outcomes from the countries included in the EU28 
were isolated and compared with the WHO European 
region and with global data. According to WHO, the 
European region includes, in addition to the 28 European 
countries that were part of the EU28 in 2017, another 
22 countries (appendix p 9). WHO divides the European 
region into three subregions: western, central, and 
eastern Europe (appendix p 15).
In our analysis we included 13 neurological disorders. 
We chose to exclude traumatic brain injury and spinal 
cord injury because post­traumatic disorders were 
out side the scope of our investigation. The burden of 
neurological disorders was calculated as incidence, pre­
valence, mortality, DALYs, YLLs, and YLDs, totally and, 
separately, for each disorder.
DALYs, YLLs, and YLDs
To compare deaths and non­fatal outcomes within and 
between diseases, a unique indicator was used, DALYs, 
which is the sum of YLLs and YLDs. YLLs are the product 
of the number of deaths multiplied by the standard life 
See Online for appendix
Research in context
Evidence before this study
We searched PubMed on Feb 10, 2019, and March 3, 2020, 
for articles focusing on the incidence, prevalence, mortality, 
and overall burden of neurological disorders in Europe using the 
search terms (“Burden of disease” OR “Epidemiology” OR 
“Costs”) AND (“Neurology” OR “Neurologic disease”) AND 
(“Europe”) with no language or time restrictions. Despite the 
publication of numerous studies on the frequency and outcome 
of neurological disorders in Europe, we found only a few and 
older reports on the burden of disease on a national basis or in 
selected age groups, and virtually no studies comparing various 
clinical conditions and different countries. The economic costs of 
disorders of the brain in Europe were calculated by the European 
Brain Council, but the corresponding burden was not measured. 
Worldwide and country-specific data on the burden of 
neurological disorders, in general and by type, have been 
provided only by the Global Burden of Diseases (GBD) studies. 
During the period 1990–2016, neurological disorders accounted 
for an increasing number of disability-adjusted life-years 
(DALYs). However, no data from the 27 EU countries plus the UK 
(EU28) were highlighted. As the population of EU28 is ageing 
and the prevalence of neurological disorders increases with age, 
the corresponding burden will increase even further in that area. 
Additionally, because the growth, ageing, and sociodemographic 
characteristics of the European population differ between the 
EU28 and the other countries in the larger WHO region, the 
burden of neurological disorders is expected to differ.
Added value of this study
This study updates the previous investigation covering the 
period 1990–2016 by providing data for the year 2017. 
In the EU28, neurological disorders were the third most 
common source of DALYs, after cardiovascular diseases and 
cancer. Comparing data from the EU28 to the three WHO 
European regions (western, central, and eastern Europe), 
substantial differences were found across countries in the 
burden of neurological disorders, which might reflect not only 
the structure of the underlying populations, but also the 
different approaches of the local health-care facilities in the 
introduction of prevention and treatment measures. 
This difference was particularly true for neurodegenerative 
diseases for which robust preventive measures and disease-
modifying treatments are not available. During the study 
period, the burden of headache was unchanged, whereas the 
burden of stroke decreased and the burden of Alzheimer’s 
disease and other dementias increased, but at different paces 
in the EU28 and the WHO European regions.
Implications of the available evidence
Because of the ageing of the European population, the EU28 is 
facing an increasing burden attributable to neurological 
disorders, presenting the governments with an increasing 
demand for acute care, rehabilitation, and support services. 
The growing numbers of affected individuals and the 
corresponding numbers of neurological DALYs and deaths 
should call for action to address these diseases. particularly 
neurodegenerative diseases that are still in need of robust 
preventive measures and disease-modifying treatments. 
The results of this study can be used by the health authorities 
and local governments to consider the burden of neurological 
disorders that could be addressed with preventive and 
therapeutic measures.
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expectancy at the age of death. Standard life expectancy is 
obtained from the lowest observed age­specific rates of 
mortality among populations in the world greater than 
5 million.6 YLDs are the product of the prevalence 
of individual sequelae of each disease multiplied by a 
disability weight, quantifying the severity of a sequela as 
a number between 0 (representing full health) and 1 
(representing death). Disability weights were estimated 
in nine US population surveys and an open­access 
internet survey in which respondents were asked to 
choose the healthier option between random pairs of 
health states that were presented with a short description 
of the main features.7
Non­fatal estimates were obtained from systematic 
reviews of published and unpublished reports, records of 
health claims, survey microdata, registries, and disease 
surveillance systems. These data have been included in a 
single repository, the Global Health Data Exchange.8 
Non­fatal data were analysed using DisMod­MR 2.1, a 
Bayesian meta­regression tool that adjusts datapoints for 
variations in study methods among different sources 
and enforces consistency between data obtained from 
different measures, such as incidence and prevalence. 
A different model was used for brain cancer according 
to the respective GBD analysis.9 For each disease, a 
parsimonious set of sequelae was selected that best 
described the different aspects of the various con­
sequences of a disease. Each sequela is estimated 
separately (appendix).
Mortality estimates
All­cause mortality rates were estimated from vital 
registration data in countries with complete coverage. For 
other countries, the probabilities of death before age 
5 years and between ages 15 years and 60 years 
were estimated from verbal autopsies. Using model 
life tables, these probabilities were converted into 
age­specific death rates by sex, year, and location. The 
cause of death was classified using subsequent versions of 
the International Classification of Diseases (or bespoke 
classifications in some countries). When coded data were 
less informative or in the absence of a specific diagnosis, 
causes of death were redistributed to more precise codes.6 
Each death was assigned a single underlying cause. The 
mortality attributable to each cause is the product of the 
attributable fraction and the mortality due to the underlying 
disease. Causes of death were analysed using the cause of 
death ensemble model, a highly syste matised tool running 
many different models on the same data and choosing an 
ensemble of models that best reflects the available input 
data. To enforce consistency, the sum of all cause­specific 
mortality rates was scaled to all­cause mortality rates in 
each category defined by age, sex, location, and year.
Socio-demographic index
Data were stratified by socio­demographic index (SDI), a 
composite indicator of sociodemographic development 
reflecting the geometric mean of normalised values of 
a location’s income per capita, the average number of 
years of educational attainment in the population aged 
15 years and over, and the total fertility rate. Countries 
and territories were grouped into five quintiles of high, 
high­middle, middle, low­middle, and low SDI on the 
basis of their 2017 values.6
DALYs were computed for the entire world, for 
the EU28, WHO Europe, the three WHO European 
subregions, and for each European country separately, 
and analysed by age, sex, and year.
With reference to the measure of sociodemographic 
development, European countries were stratified into 
two groups: high­SDI countries (Andorra, Austria, 
Belgium, Croatia, Cyprus, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, Greece, Iceland, 
Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, 
the Netherlands, Norway, Poland, Russia, Slovakia, 
Slovenia, Sweden, Switzerland, and the UK) and 
high­middle­SDI countries (Armenia, Azerbaijan, 
Belarus, Bulgaria, Georgia, Hungary, Israel, Kazakhstan, 
Macedonia, Montenegro, Portugal, Romania, Serbia, 
Spain, Turkey, and Ukraine). Only Moldova was classified 
as a middle­SDI country.
Standardisation and uncertainty measures
Unless otherwise specified, all rates were age­standardised 
using the GBD standard (appendix p 45). The uncertainty 
of all estimates was propagated throughout all the 
calculations by creating 1000 values for each estimate of 
the burden and aggregating across causes and locations at 
the level of each of the 1000 values for all intermediate 
steps in the calculation. The lower and upper bounds of 
the 95% uncertainty intervals (UIs) were the 25th and 
975th values of the ordered 1000 values. Significant 
differences were established if 975 or more of the ordered 
1000 values of difference were on either side of zero. 
Definitions, imputation procedures and modelling 
strategies for major neurological disorders are described in 
the appendix (pp 47–147).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. EB and GD had access to all raw data. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
In 2017, the total population in the EU28 was 
512·4 million and the population of WHO Europe region 
was 925·6 million. In the same year, 307·9 million 
neuro logical diseases were counted in the EU28, 
74·5 million of which were newly diagnosed (table 1). In 
the WHO Europe region 540·3 million neurological 
diseases were counted, 133·0 million of which were 
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newly diagnosed (table 1). The total number of DALYs in 
patients with neurological disorders was 21·0 million 
(95% UI 18·5–23·9) in the EU28 and 41·1 million 
(36·7–45·9) in the WHO European region and the total 
number of deaths was 1·1 million (1·09–1·14) in 
the EU28 and 1·97 million (1·95–2·01) in the WHO 
European region (table 1). In 2017, the worldwide burden 
of neurological disorders accounted for 280·0 million 
(251·4–312·2) DALYs. In the EU28, neurological 
disorders ranked third for DALYs (after cancer and 
EU28 WHO European region Global
Total Age standardised rate 
per 100 000
Total Age-standardised rate 
per 100 000
Total Age-standardided rate per 
100 000
All neurological diseases
DALYs 21 046 899 
(18 499 198–23 863 193)
190 
(160–225)
41 103 486 
(36 655 558–45 935 037)
232 
(201–266)
279 895 042 
(251 440 223–312 210 489)
278 
(250–310)
Deaths 1 116 038 
(1 094 328–1 142 613)
8 
(8–8)
1 974 840 
(1 947 870–2 012 204)
10 
(10–10)
9 927 123 
(9 771 333–10 100 744)
12 
(12–12)
Prevalence 307 859 199 
(291 599 989–327 023 248)
4 137 
(3 900–4 395)
540 277 716 
(510 725 114–573 264 505)
4089 
(3 856–4 350)
3 868 780 576 
(3 644 294 271–4 129 974 156)
3791 
(3569–4 049)
YLDs 8 622 940 
(6 072 621–11 333 906)
99 
(69–133)
15 213 540 
(10 755 558–20 029 063)
101 
(71–135)
93 483 900 
(65 716 638–125 511 962)
92 
(64–123)
YLLs 12 423 960 
(12 149 237–12 714 922)
111 
(109–114)
25 889 946 
(25 502 381–26 430 347)
159 
(157–163)
186 411 142 
(182 252 461–190 710 446)
237 
(231–244)
Stroke
DALYs 7 314 978 
(6 833 270–7 768 518)
691 
(643–737)
18 831 007 
(17 874 242–19 733 892)
1198 
(1136–1256)
132 051 366 
(126 498 600–137 350 169)
1657 
(1587–1724)
Deaths 476 903 
(463 602–504 651)
38 
(37–40)
1 078 620 
(1 058 760–1 117 505)
61 
(60–63)
6 167 292 
(6 044 260–6 327 598)
80 
(79–83)
Prevalence 9 531 098 
(8 958 668–10 024 854)
971 
(921–1 021)
18 254 959 
(17 183 892–19 283 541)
1196 
(1 129–1262)
104 178 740 
(98 453 978–110 124 977)
1301 
(1229–1375)
Incidence 1 102 677 
(1 030 004–1 178 489)
107 
(101–115)
2 060 660 
(1 916 873–2 206 398)
131 
(123–141)
11 931 061 
(11 118 416–12 825 770)
151 
(140–162)
YLDs 1 621 402 
(1 191 963–2 036 972)
162 
(118–204)
3 304 779 
(2 428 732–4 165 663)
215 
(157–270)
18 695 419 
(13 574 330–23 686 932)
236 
(171–299)
YLLs 5 693 577 
(5 543 620–5 958 058)
530 
(516–552)
15 526 228 
(15 235 982–16 036 397)
983 
(965–1 016)
113 355 949 
(110 957 795–116 180 577)
1423 
(1392–1458)
Alzheimer’s disease and other dementias
DALYs 5 271 654 
(4 915 486to 5 641 197)
399 
(372–427)
7 686 392 
(7 175 157–8 205 020)
410 
(383–438)
30 521 481 
(28 529 663–32 557 921)
413 
(386–440)
Deaths 501 678 
(489 118–512 705)
35 
(34–36)
700 353 
(685 974–712 101)
36 
(35–36)
2 514 619 
(2 470 512–2 550 346)
35 
(35–36)
Prevalence 7 740 481 
(6 896 189–8 583 917)
594 
(531–657)
11 375 859 
(10 038 137–12 683 497)
612 
(541–681)
44 988 790 
(39 716 207–50 377 809)
605 
(533–676)
Incidence 1 249 178 
(1 118 954–1 390 849)
98 
(88–108)
1 851 062 
(1 653 033–2 065 251)
101 
(90–112)
7 300 645 
(6 515 684–8 133 403)
97 
(87–109)
YLDs 1 165 391 
(832 669–1 516 059)
88 
(63–114)
1 694 270 
(1 209 023–2 212 896)
90 
(64–118)
6 570 378 
(4 678 144–8 588 469)
89 
(64–117)
YLLs 4 106 264 
(3 982 651–4 213 014)
311 
(301–320)
5 992 121 
(5 844 318–6 113 018)
320 
(312–327)
23 951 105 
(23 523 645–24 326 849)
324 
(318–329)
Parkinson’s disease
DALYs 839 916 
(766 256–940 813)
70 
(63–78)
1 226 579 
(1 126 744–1 363 923)
70 
(64–78)
5 580 212 
(5 151 586–6 084 655)
72 
(67–79)
Deaths 60 812 
(55 723–67 973)
5 
(4–5)
84 599 
(80 948–93 079)
5 
(4–5)
340 639 
(324 378–355 089)
5 
(4–5)
Prevalence 1 215 045 
(996 237–1 457 870)
105 
(86–125)
1 838 098 
(1 506 704–2 220 458)
107 
(88–128)
8 525 404 
(7 037 337–10 185 559)
109 
(90–131)
incidence 150 667 
(124 575–180 761)
13 
(11–16)
225 529 
(185 864–271 669)
13 
(11–16)
1 025 939 
(854 090–1 229 873)
13 
(11–16)
YLDs 170 916 
(117 642–233 979)
15 
(10–20)
257 986 
(178 581–354 467)
15 
(10–21)
1 218 972 
(823 711–1 662 213)
16 
(11–22)
YLLs 669 000 
(612 867–764 328)
55 
(51–63)
968 593 
(924 800–1 088 287)
55 
(52–62)
4 361 241 
(4 182 792–4 578 722)
57 
(55–60)
(Table 1 continues on next page)
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EU28 WHO European region Global
Total Age-standardised rate 
per 100 000
Total Age-standardised rate 
per 100 000
Total Age-standardised rate per 
100 000
(Continued from previous page)
Motor neuron disease
DALYs 252 987 
(240 153–264 173)
31 
(29–32)
314 523 
(298 988–348 088)
24 
(23–26)
878 518 
(841 386–966 073)
11 
(10–12)
Deaths 11 495 
(10 900–12 020)
1 
(1–1)
13 410 
(12 728–14 790)
1 
(1–1)
34 068 
(32 796–37 053)
0 
(0–0)
Prevalence 42 937 
(38 970–47 145)
6 
(5–7)
51 711 
(46 991–56 707)
4 
(4–5)
237 053 
(211 191–264 106)
3 
(3–3)
Incidence 13 010 
(12 311–13 767)
1 
(1–2)
15 728 
(14 766–16 723)
1 
(1–1)
67 322 
(60 666–74 311)
1 
(1–1)
YLDs 9131 
(6492–12 227)
1 
(1–2)
10 998 
(7 822–14 720)
1 
(1–1)
50 416 
(35 744–67 546)
1 
(1–1)
YLLs 243 856 
(231 168–254 703)
29 
(28–31)
303 526 
(287 735–337 104)
23 
(22–25)
828 102 
(796 699–917 135)
11 
(10–12)
Multiple sclerosis
DALYs 282 765 
(233 418–328 839)
39 
(32–46)
391 078 
(327 333–453 473)
32 
(26–37)
1 084 757 
(942 878–1 237 344)
13 
(12–15)
Deaths 5601 
(3954–6056)
1 
(0–1)
7413 
(5673–8395)
1 
(0–1)
20 655 
(17 721–22 238)
0 
(0–0)
Prevalence 522 674 
(473 413–579 422)
77 
(69–85)
699 238 
(635 288–772 355)
59 
(53–65)
1 761 078 
(1 598 226–1 947 909)
22 
(20–24)
Incidence 11 847 
(10 861–13 042)
3 
(2–3)
17 544 
(16 068–19 308)
2 
(2–2)
54 895 
(50 054–60 812)
1 
(1–1)
YLDs 132 159 
(95 038–171 558)
20 
(14–26)
178 020 
(127 760–230 616)
15 
(11–20)
456 556 
(327 739–595 013)
6 
(5–8)
YLLs 150 607 
(110 315–166 542)
19 
(14–22)
213 059 
(169 517–254 322)
17 
(14–20)
628 202 
(563 020–682 386)
8 
(7–9)
Brain and nervous system cancer
DALYs 964 964 
(789 495–1 033 050)
140 
(117–153)
1 668 047 
(1 439 524–1 799 509)
147 
(130–163)
8 744 765 
(7 652 109–9 554 150)
112 
(98–123)
Deaths 35 917 
(27 137–38 316)
4 
(3–4)
56 246 
(45 620–59 326)
4 
(3–4)
247 143 
(212 969–265 001)
3 
(3–3)
Prevalence 330 074 
(270 005–360 630)
55 
(46–62)
462 982 
(398 536–511 728)
45 
(40–52)
1 705 702 
(1 470 989–1 894 771)
22 
(19–24)
Incidence 70 026 
(54 549–75 620)
10 
(8–11)
102 219 
(86 050–109 460)
9 
(8–10)
405 218 
(351 030–442 624)
5 
(4–6)
YLDs 30 368 
(21 160–40 887)
5 
(3–6)
43 489 
(31 024–57 873)
4 
(3–5)
166 947 
(117 460–222 977)
3 
(2–3)
YLLs 934 596 
(766 157–997 931)
135 
(113–148)
1 624 558 
(1 404 505–1 753 504)
143 
(127–158)
8 577 818 
(7 527 040–9 359 303)
110 
(97–121)
Meningitis
DALYs 84 550 
(77 767–97 340)
20 
(18–24)
288 614 
(267 659–324 772)
38 
(35–43)
20 370 870 
(17 800 140–23 356 670)
293 
(254–337)
Deaths 2033 
(1947–2224)
0 
(0–0)
5 483 
(5 253–6 125)
1 
(1–1)
288 021 
(254 287–333 240)
4 
(4–5)
Prevalence 183 151 
(153 769–216 836)
33 
(28–39)
505 430 
(430 502–591 790)
53 
(45–62)
10 572 886 
(8 836 735–12 552 236)
139 
(116–165)
Incidence 92 542 
(82 041–105 206)
22 
(19–25)
232 423 
(205 684–266 898)
30 
(26–35)
5 045 411 
(4 435 073–5 877 841)
71 
(62–83)
YLDs 17 079 
(12 032–22 999)
4 
(3–5)
45 301 
(31 738–60 745)
5 
(4–7)
933 935 
(652964–1255126)
13 
(9–17)
YLLs 67 471 
(64 007–80 231)
17 
(16–21)
243 313 
(230 129–280 048)
33 
(31–39)
19 436 936 
(16 935 143–22 335 832)
281 
(244–324)
(Table 1 continues on next page)
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cardiovascular diseases) and deaths (after cardiovascular 
diseases and cancer). These diseases comprised 13·4% 
(10·3–17·1) of global DALYs and 19·5% (18·0–21·3) of 
deaths. In the WHO European region, neurological 
disorders ranked third for DALYs and deaths (after 
cardiovascular diseases and neoplasms). The proportion 
of total DALYs attributable to neurological disorders 
was 13·1% (12·8–13·15) and the proportion of deaths 
was 19·0% (19·0–19·1). The percentage of DALYs 
attributable to neurological disorders was lowest in 
western Europe (14·0% [12·7–15·2]) and highest in 
central Europe (15·1% [13·9–16·2]). The proportion of 
EU28 WHO European region Global
Total Age-standardised rate 
per 100 000
Total Age-standardised rate 
per 100 000
Total Age-standardised rate per 
100 000
(Continued from previous page)
Encephalitis
DALYs 57 720 
(50 302–63 183)
11 
(10–12)
270 736 
(236 953–292 768)
34 
(30–38)
5 112 280 
(4 541 340–5 764 967)
71 
(63–79)
Deaths 1729 
(1337–1829)
0 
(0–0)
5953 
(4 631–6266)
1 
(0–1)
92 370 
(83 134–107 936)
1 
(1–1)
Prevalence 142 435 
(74 374–234 773)
22 
(12–35)
315 202 
(173 810–507 091)
29 
(17–46)
6 724 882 
(3 731 161–10 760 385)
86 
(48–137)
Incidence 47 411 
(46 409–48 414)
9 
(9–9)
110 769 
(108 844–112 873)
12 
(12–12)
2 220 535 
(2 289 100–2 225 245)
30 
(29–30)
YLDs 9 372 
(6 386–12 593)
2 
(1–2)
22 773 
(15 651–30 309)
3 
(2–3)
524 114 
(365 488–691 266)
7 
(5–9)
YLLs 48 348 
(41 387–51 476)
10 
(8–11)
247 963 
(214 185–269 172)
33 
(28–36)
4 588 167 
(4 059 515–5 230 709)
65 
(57–73)
Tetanus
DALYs 649 
(558–755)
0 
(0–0)
2127 
(1860–2770)
0 
(0–0)
2 449 433 
(1 736 526–3 201 172)
35 
(25–46)
Deaths 39 
(33–46)
0 
(0–0)
82 
(72–100)
0 
(0–0)
38 134 
(25 893–487 71)
1 
(0–1)
Prevalence 4 
(3–5)
0 
(0–0)
160 
(133–187)
0 
(0–0)
59 583 
(56 726–62 572)
1 
(1–1)
Incidence 68 
(58–82)
0 
(0–0)
164 
(140–205)
0 
(0–0)
79 192 
(53 360–105 261)
1 
(1–1)
YLDs 1 
(0–1)
0 
(0–0)
4 
(3–7)
0 
(0–0)
1695 
(1065–2541)
1 
(1–1)
YLLs 649 
(558–754)
0 
(0–0)
2122 
(1856–2765)
0 
(0–0)
2 447 740 
(1 734 885–3 199 044)
36 
(25–47)
Epilepsy
DALYs 781 549 
(512 4583–1 168 936)
140 
(90–211)
1 479 134 
(1 063 428–2 050 641)
158 
(113–220)
14 793 945 
(11 417 678–18 991 487)
196 
(151–252)
Deaths 9 526 
(7 286–10 097)
1 
(1–1)
15 370 
(12 663–16 443)
1 
(1–1)
130 237 
(116 998–150 774)
2 
(2–2)
Prevalence 2 244 668 
(1 496 976–2 977 225)
399 
(266–529)
3 742 828 
(2 718 716–4 823 770)
385 
(280–497)
27 288 268 
(21 576 010–33 443 826)
359 
(284–441)
Incidence 184 947 
(124 646–244 171)
37 
(25–50)
309 286 
(221 551–399 256)
35 
(25–46)
2 470 759 
(1 905 450–3 062 903)
33 
(26–41)
YLDs 523 003 
(259 741–908 273)
96 
(48–166)
942 629 
(528 597–1 512 164)
100 
(57–160)
8 561 880 
(5 380 607–12 551 498)
114 
(72–166)
YLLs 258 546 
(219 592–274 228)
44 
(40–47)
536 505 
(490 237–585 052)
58 
(53–64)
6 232 066 
(5 709 753–7 289 706)
83 
(76–97)
Migraine
DALYs 4 231 019 
(2 740 462–6 048 715)
770 
(495–1115)
7 401 471 
(4 810 162–10 539 348)
735 
(473–1056)
47 245 390 
(29 986 692–68 669 318)
597 
(378–866)
Prevalence 112 207 672 
(104 739 016–119 973 469)
20 646 
(19 234–22 225)
195 794 407 
(182 677 431–209 186 190)
19 650 
(18 270–21 082)
1 331 364 642 
(1 237 219 585–1 433 357 249)
16 828 
(15 638–18 119)
Incidence 7 506 784 
(6 829 187–8 173 362)
1724 
(1568–1883)
13 669 490 
(12 467 555–14 861 052)
1 641 
(1 493–1 789)
112 933 549 
(102 829 920–122 899 843)
1477 
(1344–1607)
YLDs 4 231 019 
(2 740 461–6048715)
770 
(495–1115)
7 401 471 
(4 810 162–10 539 348)
735 
(473–1056)
47245391 
(29986693–68669319)
597 
(379–866)
(Table 1 continues on next page)
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deaths attributable to neurological disorders was 21·8% 
(21·6–22·1) in eastern Europe, 22·6% (22·3–23·0) in 
central Europe, and 21·46% (21·2–21·9) in western 
Europe (appendix p 16).
Stroke (7·3 million [95% UI 6·7–7·9]; 35% [35–38), 
dementia (5·3 million [4·9–5·6]; 25% [23–28]), and 
headache (migraine and tension­type headache 
combined; 4·8 million [3·1–7·1]; 23% [19–29]) were, in 
decreasing order, the three commonest sources of DALYs 
in the EU28 (table 1; figure 1; appendix p 17). Stroke 
also was the leading source of burden attributable to 
neurological disorders in the WHO European 
region, accounting for the largest proportion of DALYs 
(18·3 million [17·9–19·7]; 45·6% [42·0–49·0]), followed 
by headache (8·6 million [5·4–12·6]; 20·6% [14·7–27·2]) 
and dementia (7·7 million, 7·1–8·3]; 18·7% [17·3–20·2]). 
In western Europe, the leading contributor was stroke 
(28% [25·5–31·5]; figure 1), which accounted for 
4·7 million DALYs (4·4–5·0). Stroke also predominated 
in central Europe (55% [50·3–59·5]) with 3·3 million 
DALYs (3·1–3·5) and eastern Europe (62% [57·3–66·7]) 
with 8·2 million (7·8–8·5). All the other neurological 
disorders accounted for lower numbers and rates 
(appendix p 17).
In the EU28, the total number of DALYs was higher in 
women (12·0 million [9·9–14·5]) than in men (9·1 million 
[7·6–10·8]). The major contributors to the burden of 
neurological disorders were dementia and stroke, the 
attributable proportions of which increased substantially 
with age both for the number of DALYs and for DALY 
rates (figure 2). We found substantial sex differences in 
the number of DALYs and in age­standardised DALY 
rates in all age groups for dementia, migraine, and 
multiple sclerosis (that were higher in women) and for 
stroke and Parkinson’s disease (that were higher in men; 
appendix p 10). DALYs and DALY rates for epilepsy and 
brain cancer were also higher in men than in women. 
Findings were similar in the WHO European region for 
both sexes and for women and men separately 
(appendix p 12). In the EU28 the peak in the number of 
DALYs and DALY rates was in people aged 80–84 years 
for both sexes. By contrast, in the WHO European region 
the burden peaked in women aged 80–84 years and in 
men aged 75–79 years.
Dementia, stroke, and headache differed when 
comparing findings in western, central, and eastern 
Europe. In western Europe the burden was predominantly 
represented by dementia and stroke after age 70 years in 
both sexes, whereas stroke was the strongest contributor in 
those aged 40–89 years in central Europe and 50–89 years 
in eastern Europe (appendix p 12).
The changes in all­age and age­standardised DALY 
rates of neurological disorders in the EU28 and WHO 
European region between 1990 and 2017 are shown in 
EU28 WHO European region Global
Total Age-standardised rate 
per 100 000
Total Age-standardised rate 
per 100 000
Total Age-standardised rate per 
100 000
(Continued from previous page)
Tension-type headache
DALYs 600 667 
(343 433–936 239)
101 
(57–159)
1 163 732 
(664 951–1 799 904)
110 
(63–173)
7 096 415 
(4 044 590–11 213 525)
90 
(51–142)
Prevalence 173 696 347 
(158 485 543–190 762 959)
30 871 
(28 014–33 930)
309 890 284 
(281 758 135–340 323 834)
31 022 
(28 086–34 097)
2 331 334 677 
(2 110 373 311–2 575 461 450)
29 810 
(27 057–32 943)
Incidence 63 611 672 
(57 147 715–69 565 055)
11 725 
(10 423–12 971)
114 411 512 
(102 667 592–125 554 761)
11 805 
(10 490–13 036)
882 441 388 
(783 241 228–975 064 340)
11 371 
(10 058–12 591)
YLDs 600 667 
(343 433–936 239)
101 
(57–159)
1 163 732 
(664 951–1 799 904)
110 
(63–173)
7 096 415 
(4 044 591–11 213 526)
90 
(51–143)
Other neurological disorders
DALYs 363 480 
(314 552–426 877)
65 
(54–79)
599 059 
(517 397–698 284)
63 
(54–76)
3 965 609 
(3 265 588–4 845 474)
53 
(43–65)
Deaths 10 303 
(9219–10 814)
1 
(1–1)
14 052 
(12 762–14 637)
1 
(1–1)
53 946 
(51 552–59 030)
1 
(1–1)
Prevalence 2613 
(1736–3517)
0 
(0–1)
4364 
(2939–5868)
0 
(0–1)
38 870 
(25 596–53 211)
1 
(0–1)
Incidence ·· 0 
(0–0)
·· 0 
(0–0)
·· 0 
(0–0)
YLDs 112 433 
(68 271–174 266)
23 
(13–37)
206 737 
(130 672–304 277)
24 
(15–36)
1 961 790 
(1 276 347–2 823 819)
27 
(17–38)
YLLs 251 047 
(232 719–264 643)
42 
(39–45)
392 321 
(369 776–410 145)
40 
(37–42)
2 00 3 820 
(1 856 755–2 269 519)
27 
(25–31)
Data are n (95% UI). DALYs=disability-adjusted life-years. EU28=the 27 EU countries plus the UK. YLDs=years lived with disability. YLLs= years of life lost. UI=uncertainty interval.
Table 1: Comparison of DALYs, deaths, prevalence, YLDs, and YLLs for the EU28, WHO European region, and globally for all neurological diseases and each subcategory separately in 2017
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table 2, and for global comparisons, in the appendix (p 19). 
In the EU28, dementia accounted for a 63% (95% UI 
58 to 66) increase in DALYs and a 93% (88 to 97) increase 
in deaths. Similar changes were found for Parkinson’s 
disease (61% increase [31 to 69]) and motor neuron 
disease (60% increase [49 to 69]), for which we found a 
91% (75 to 102) increase in deaths. Modest increases in 
DALYs and other measures were observed for multiple 
sclerosis and, to a lesser extent, migraine and tension­
type headache (appendix p 19). By contrast, a 30% decrease 
(–27 to –33) in stroke DALYs was observed despite a 25% 
(20 to 30) increase in prevalence and a 28% (22 to 34) 
increase in YLDs. A significant decrease in all measures 
of burden was also observed for encephalitis, meningitis, 
and tetanus (appendix p 19). We found a 53% increase 
(3 to 64) in deaths for epilepsy and 43% (0 to 54) in deaths 
for brain cancers. Brain cancers showed a 161% (98 to 192) 
increase in prevalence. A 41% (39 to 44) increased 
prevalence was also found for multiple sclerosis. With 
some exceptions, in the EU28 all measures differed only 
slightly from those in the WHO European region but 
significantly from the global estimates (appendix p 19).
In the EU28 and WHO European region, age­
standardised DALY rates showed a significant decrease 
for stroke and infections and a modest, but still 
significant, decrease for dementia. We found a significant 
increase only for motor neuron disease in the EU28 
(table 2). Findings were similar for deaths (appendix p 19), 
whereas prevalence (all age and age standardised) 
increased for all clinical conditions apart from 
head ache, although at a variable speed between regions 
(appendix p 19).
In 1990, in high­SDI European countries stroke was 
the leading disease, accounting for 1286 age­standardised 
DALYs per 100 000 (95% UI 1228 to 1341), followed by 
migraine (676 [433 to 975]), and dementia (430 [403 to 
458]; tables 3). Migraine, stroke, and dementia ranked 
first, second, and third in 2017, but while the age­
standardised DALY rate for stroke was substantially 
lower in comparison to 1990 levels, at 650 (597 to 703; 
49% decrease [–52 to –47)), the age­standardised DALY 
rate for migraine and dementia remained similar at 
674 (431 to 970; unchanged) and 399 (373 to 426; 7% 
decrease; –9 to –5; table 3), respectively. In high­middle­
SDI countries, stroke and dementia ranked first and 
third both in 1990 and in 2017, but the age­standardised 
rate of stroke decreased by 37% (–40 to –35) from 
3196 (3097 to 3294) in 1990, while the decrease in the age­
standardised rate of dementia was only 6% (–8 to –3; 
table 3). Epilepsy showed a 6% (–23 to 14) non­significant 
decrease in high­SDI countries and a 27% (–42 to –9) 
decrease in high­middle­SDI countries. Notably, the 
disease which showed the largest increase of prevalence 
and DALY rates, but only in high­SDI countries, 
was motor neuron disease (11% [6 to 16]). Parkinson’s 
disease was next, showing a non­significant increase 
(6% [–16 to 11) in high­SDI countries but a significant 
decrease (–4% [–10 to 0) in high­middle SDI countries).
During the study period, all­age DALY numbers, 
deaths, and prevalence of neurological disorders varied 
across countries (appendix p 27), with increases in 
Albania, Andorra, Armenia. Azerbaijan, Belarus, Bosnia 
and Herzegovina, Bulgaria, Georgia, Greece, Lithuania, 
Macedonia, Malta, Moldova, Montenegro, Romania, 
Russia, Serbia, Turkmenistan, Ukraine, and Uzbekistan, 
and no change or decrease in the other countries. 
By contrast, age­standardised DALY and death rates 
decreased in all WHO European region countries, except 
for Azerbaijan, Turkmenistan, and Uzbekistan, where 
both measures increased, and Albania and Bosnia and 
Figure 1: Contribution of each disease to the overall burden of neurological disorders in the EU28, western, 
central, and eastern Europe in 2017
Percentages represent proportion of DALYs. DALYs=disability-adjusted life-years. EU28=the 27 countries in the EU 
plus the UK.
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Herzegovina, where death rates were unchanged. We 
found a modest increase in age­standardised prevalence 
rates of neurological disorders in Azerbaijan, Bosnia and 
Herzegovina, Lithuania, Montenegro, the Netherlands, 
and Switzerland. We found an almost universal decrease 
in standardised DALY rates in all countries (maximally 
represented by a reduction in YLLs and, only to a lesser 
extent, by a reduction in YLDs), the only exceptions being 
Azerbaijan, Turkmenistan, and Uzbekistan. By contrast, 
except for Estonia, Latvia and Ukraine, where a decrease 
of all raw numbers was also observed, prevalent 
cases, deaths, DALYs, YLLs, and YLDs all increased in 
Azerbaijan, Cyprus, Finland, France, Greece, Iceland, 
Israel, Kazakhstan, Macedonia, Malta, Montenegro, the 
Netherlands, Tajikistan, Turkmenistan, and Uzbekistan 
(appendix p 27).
Discussion
In 2017, neurological disorders were among the most 
common sources of health loss in the EU28 and the WHO 
European region. Although globally neurological dis orders 
were the second largest contributor to DALYs and the 
second largest cause of death, in both European regions 
neurological disorders ranked third for DALYs and deaths.
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Figure 2: EU28 and WHO European region DALYs
Total number of DALYs (A) and age-standardised DALY rates (B) by age group including both sexes in 2017. DALYs=disability-adjusted life-years. 
EU28=the 27 countries in the EU plus the UK.
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EU28 WHO European region
Age-
standardised 
rate, 1990
Age-
standardised 
rate, 2017
Change 
from 1990 
to 2017
Total, 1990 Total, 2017 Change 
from 
1990 to 
 2017
Age-
standardised 
rate, 1990
Age-
standardised 
rate, 2017
Change 
from 1990 
to 2017
Total, 1990 Total, 2017 Change 
from 
1990 to 
 2017
Stroke
DALYs 1489 
(1434 to 
1538)
691 
(643 to 737)
–54% 
(–56 to 
–52)
10 446 307 
(10 075 476 to 
10 789 349)
7 314 978 
(6 833 270 to 
7 768 518)
–30% 
(–33 to 
–27)
2012 
(1946 to 
2075)
1198 
(1136 to 
1256)
–40% 
(–42 to 
–39)
21 991 312 
(21 276 861 to 
22 669 254)
18 831 007 
(17 874 242 to 
19 733 892)
–14% 
(–17 to 
–12)
Deaths 86 
(85 to 87)
38 
(37 to 40)
–57% 
(–58 to 
–54)
619 264 
(611 400 to 
627 766)
476 903 
(463 602 to 
504 651)
–23% 
(–25 to 
–19)
112 
(111 to 113)
61 
(60 to 63)
–45% 
(–47 to 
–44)
1 207 823 
(1 195 003 to 
1 225 524)
1 078 620 
(1 058 760 to 
1 117 505)
–11% 
(–13 to –7)
Prevalence 1117 
(1073 to 
1167)
971 
(921 to 
1 021)
–13% 
(–16 to 
–10)
7 603 547 
(7 294 082 to 
7 947 767)
9 531 098 
(8 958 668 to 
10 024 854)
25% 
(20 to 30)
1285 
(1236 to 
1345)
1196 
(1129 to 
1262)
–7% 
(–10 to –4)
13 870 323 
(13 323 695 to 
14 529 934)
18 254 959 
(17 183 892 to 
19 283 541)
32% 
(27 to 36)
YLDs 185 
(135 to 232)
162 
(118 to 204)
–13% 
(–16 to –9)
1 266 025 
(925 645 to 
1 584 998)
1 621 402 
(1 191 963 to 
2 036 972)
28% 
(22 to 34)
229 
(167 to 287)
215 
(157 to 270)
–6% 
(–9 to –4)
2 475 049 
(1 797 028 to 
3 105 300)
3 304 779 
(2 428 732 to 
4 165 663)
34% 
(29 to 38)
YLLs 1304 
(1284 to 
1321)
530 
(516 to 552)
–59% 
(–61 to 
–58)
9 180 282 
(9 044 047 to 
9 307 537)
5 693 577 
(5 543 620 to 
5 958 058)
–38% 
(–40 to 
–35)
1783 
(1761 to 1813)
983 
(965 to 
1016)
–45% 
(–46 to 
–43)
19 516 263 
(19 283 622 to 
19 856 420)
15 526 228 
(15 235 982 to 
16 036 397)
–20% 
(–22 to 
–18)
Alzheimer’s disease and other dementias
DALYs 444 
(416 to 473)
399 
(372 to 427)
–10% 
(–12 to –8)
3 240 468 
(3 038 789 to 
3 453 552)
5 271 654 
(4 915 486 to 
5 641 197)
63% 
(58 to 66)
446 
(418 to 476)
410 
(383 to 438)
–8% 
(–10 to –7)
4 774 751 
(4 471 802 to 
5 088 817)
7 686 392 
(7 175 157 to 
8 205 020)
61% 
(58 to 63)
Deaths 38 
(38 to 39)
35 
(34 to 36)
–8% 
(–11 to –6)
260 244 
(258 513 to 
262 203)
501 678 
(489 118 to 
512 705)
93% 
(88 to 97)
38 
(38 to 39)
36 
(35 to 36)
–7% 
(–9 to –6)
376 119 
(372 115 to 
379 282)
700 353 
(685 974 to 
712 101)
86% 
(83 to 89)
Prevalence 654 
(580 to 727)
594 
(531 to 657)
–9% 
(–11 to –8)
4 788 372 
(4 216 845 to 
5 360 285)
7 740 481 
(6 896 189 to 
8 583 917)
62% 
(57 to 67)
658 
(580 to 734)
612 
(541 to 681)
–7% 
(–8 to –6)
7 074 259 
(6 222 667 to 
7 942 113)
11 375 859 
(10 038 137 to 
12 683 497)
61% 
(57 to 65)
YLDs 97 
(69 to 126)
88 
(63 to 114)
–9% 
(–9 to –9)
706 265 
(504 015 to 
919 170)
1 165 391 
(832 669 to 
1 516 059)
65% 
(59 to 71)
97 
(69 to 126)
90 
(64 to 118)
–7% 
(–8 to –5)
1 033 646 
(741 294 to 
1 345 291)
1 694 270 
(1 209 023 to 
2 212 896)
64% 
(59 to 69)
YLLs 347 
(345 to 349)
311 
(301 to 320)
–10% 
(–13 to –9)
2 534 204 
(2 517 343 to 
2 553 205)
4 106 264 
(3 982 651 to 
4 213 014)
62% 
(57 to 66)
349 
(346 to 352)
320 
(312 to 327)
–8% 
(–10 to –7)
3 741 105 
(3 702 678 to 
3 772 727)
5 992 121 
(5 844 318 to 
6 113 018)
60% 
(57 to 63)
Parkinson’s disease
DALYs 68 
(63 to 82)
70 
(63 to 78)
2% 
(–17 to 7)
522 267 
(482 466 to 
625 465)
839 916 
(766 256 to 
940 813)
61% 
(31 to 69)
69 
(63 to 80)
70 
(64 to 78)
2% 
(–10 to 5)
781 347 
(720 120 to 
908 025)
1 226 579 
(1 126 744 to 
1 363 923)
57% 
(38 to 62)
Deaths 5 
(4 to 6)
5 
(4 to 5)
2% 
(–19 to 8)
34 236 
(33 270 to 
41 800)
60 812 
(55 723 to 
67 973)
78% 
(40 to 88)
4 
(4 to 5)
5 
(4 to 5)
2% 
(–13 to 6)
49 050 
(47 428 to 
57 737)
84 599 
(80 948 to 
93 079)
72% 
(47 to 79)
Prevalence 94 
(79 to 112)
105 
(86 to 125)
11% 
(7 to 15)
704 533 
(584 038 to 
840 424)
1 215 045 
(996 237 to 
1 457 870)
72% 
(65 to 80)
100 
(82 to 119)
107 
(88 to 128)
7% 
(5 to 10)
1 123 483 
(925 451 to 
1 344 223)
1 838 098 
(1 506 704 to 
2 220 458)
64% 
(59 to 69)
YLDs 13 
(9 to 18)
15 
(10 to 20)
11% 
(7 to 16)
99 431 
(68 796 to 
134 551)
170 916 
(117 642 to 
233 979)
72% 
(64 to 80)
14 
(10 to 19)
15 
(10 to 21)
8% 
(5 to 11)
158 046 
(107 768 to 
215 467)
257 986 
(178 581 to 
354 467)
63% 
(57 to 69)
YLLs 55 
(53 to 69)
55 
(51 to 63)
–1% 
(–22 to 6)
422 835 
(409 771 to 
526 346)
669 000 
(612 867 to 
764 328)
58% 
(23 to 68)
55 
(53 to 65)
55 
(52 to 62)
0% 
(–14 to 4)
623 301 
(601 534 to 
744 574)
968 593 
(924 800 to 
1 088 287)
55% 
(33 to 62)
Motor neuron disease
DALYs 27 
(26 to 29)
31 
(29 to 32)
12% 
(4 to 20)
157 904 
(151 812 to 
164 075)
252 987 
(240 153 to 
264 173)
60% 
(49 to 69)
22 
(19 to 26)
24 
(23 to 26)
11% 
(–5 to 27)
203 830 
(188 169 to 
229 421)
314 523 
(298 988 to 
348 088)
54% 
(38 to 75)
Deaths 1 
(1 to 1)
1 
(1 to 1)
29% 
(19 to 37)
6034 
(5821 to 
6282)
11 495 
(10 900 to 
12 020)
91% 
(75 to 102)
1 
(1 to 1)
1 
(1 to 1)
31% 
(20 to 43)
7 076 
(6 773 to 
7 536)
13 410 
(12 728 to 
14 790)
90% 
(76 to 103)
(Table 2 continues on next page)
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Age-
standardised 
rate, 1990
Age-
standardised 
rate, 2017
Change 
from 1990 
to 
 2017
Total, 1990 Total, 2017 Change 
from 
1990 to 
 2017
Age-
standardised 
rate, 1990
Age-
standardised 
rate, 2017
Change 
from 1990 
to 
 2017
Total, 1990 Total, 2017 Change 
from 
1990 to 
 2017
(Continued from previous page)
Prevalence 4 
(4 to 5)
6 
(5 to 7)
42% 
(39 to 45)
23 986 
(21 913 to 
26 169)
42 937 
(38 970 to 
47 145)
79% 
(74 to 85)
3 
(3 to 4)
4 
(4 to 5)
35% 
(32 to 37)
30 603 
(27 763 to 
33 544)
51 711 
(46 991 to 
56 707)
69% 
(64 to 74)
YLDs 1 
(1 to 1)
1 
(1 to 2)
42% 
(39 to 45)
5101 
(3618 to 
6809)
9131 
(6492 to 
12 227)
79% 
(74 to 85)
1 
(0 to 1)
1 
(1 to 1)
35% 
(32 to 37)
6509 
(4612 to 
8693)
10 998 
(7 822 to 
14 720)
69% 
(64 to 74)
YLLs 27 
(25 to 28)
29 
(28 to 31)
11% 
(3 to 19)
152 803 
(146 985 to 
158 391)
243 856 
(231 168 to 
254 703)
60% 
(48 to 69)
21 
(19 to 25)
23 
(22 to 25)
10% 
(–7 to 27)
197 322 
(181 684 to 
224 050)
303 526 
(287 735 to 
337 104)
54% 
(37 to 75)
Multiple sclerosis
DALYs 39 
(33 to 45)
39 
(32 to 46)
0% 
(–16 to 12)
226 945 
(195 825 to 
260 163)
282 765 
(233 418 to 
328 839)
25% 
(1 to 37)
33 
(28 to 38)
32 
(26 to 37)
–5% 
(–15 to 11)
326 058 
(279 079 to 
372 431)
391 078 
(327 333 to 
453 473)
20% 
(5 to 38)
Deaths 1 
(1 to 1)
1 
(0 to 1)
–6% 
(–40 to 6)
4 344 
(3 781 to 
5 021)
5601 
(3954 to 
6056)
29% 
(–21 to 
41)
1 
(1 to 1)
1 
(0 to 1)
–11% 
(–35 to 8)
6104 
(5202 to 
6645)
7 413 
(5673 to 
8395)
21% 
(–14 to 43)
Prevalence 65 
(59 to 71)
77 
(69 to 85)
18% 
(16 to 21)
369 975 
(336 977 to 
407 130)
522 674 
(473 413 to 
579 422)
41% 
(39 to 44)
52 
(47 to 58)
59 
(53 to 65)
13% 
(11 to 14)
504 285 
(457 958 to 
555 895)
699 238 
(635 288 to 
772 355)
39% 
(37 to 41)
YLDs 17 
(12 to 22)
20 
(14 to 26)
18% 
(13 to 23)
94 374 
(67 351 to 
123 083)
132 159 
(95 038 to 
171 558)
40% 
(34 to 46)
13 
(10 to 18)
15 
(11 to 20)
12% 
(9 to 16)
129 438 
(92 358 to 
168 926)
178 020 
(127 760 to 
230 616)
38% 
(33 to 42)
YLLs 22 
(18 to 25)
19 
(14 to 22)
–13% 
(–40 to 6)
132 570 
(111 714 to 
148 143)
150 607 
(110 315 to 
166 542)
14% 
(–25 to 
34)
20 
(16 to 21)
17 
(14 to 20)
–16% 
(–34 to 10)
196 620 
(162 235 to 
206 779)
213 059 
(169 517 to 
254 322)
8% 
(–17 to 37)
Brain and nervous system cancer
DALYs 153 
(136 to 171)
140 
(117 to 153)
–9% 
(–28 to 5)
823 636 
(748 909 to 
932 285)
964 964 
(789 495 to 
1 033 050)
17% 
(–11 to28)
158 
(141 to 175)
147 
(130 to 163)
–7% 
(–20 to 5)
1 435 491 
(1 289 242 to 
1 584 211)
1 668 047 
(1 439 524 to 
1 799 509)
16% 
(–1 to 28)
Deaths 4 
(4 to 5)
4 
(3 to 4)
2% 
(–25 to 9)
25 123 
(23 238 to 
28 753)
35 917 
(27 137 to 
38 316)
43% 
(0 to 54)
4 
(4 to 4)
4 
(3 to 4)
5% 
(–15 to 14)
39 568 
(36 090 to 
44 242)
56 246 
(45 620 to 
59 326)
42% 
(12 to 55)
Prevalence 24 
(22 to 27)
55 
(46 to 62)
127% 
(76 to 
168)
126 363 
(114 687 to 
142 588)
330 074 
(270 005 to 
360 630)
161% 
(98 to 
192)
21 
(19 to 24)
45 
(40 to 52)
113% 
(76 to 
150)
190 647 
(174 163 to 
212 101)
462 982 
(398 536 to 
511 728)
143% 
(97 to 176)
YLDs 3 
(2 to 3)
5 
(3 to 6)
84% 
(41 to 112)
13 971 
(9 980 to 
18 627)
30 368 
(21 160 to 
40 887)
117% 
(61 to 
142)
2 
(2 to 3)
4 
(3 to 5)
74% 
(43 to 
101)
21 212 
(15 112 to 
28 018)
43 489 
(31 024 to 
57 873)
105% 
(64 to 128)
YLLs 150 
(134 to 169)
135 
(113 to 148)
–10% 
(–30 to 3)
809 666 
(735 221 to 
917 160)
934 596 
(766 157 to 
997 931)
15% 
(–12 to 
26)
156 
(139 to 172)
143 
(127 to 158)
–8% 
(–21 to 4)
1 414 279 
(1 271 685 to 
1 561 721)
1 624 558 
(1 404 505 to 
1 753 504)
15% 
(–2 to 27)
Meningitis
DALYs 75 
(71 to 81)
20 
(18 to 24)
–74% 
(–76 to 
–69)
278 620 
(261 680 to 
296 452)
84 550 
(77 767 to 
97 340)
–70% 
(–72 to 
–65)
172 
(115 to 203)
38 
(35 to 43)
–78% 
(–81 to 
–64)
1 182 458 
(811 688 to 
1 378 097)
288 614 
(267 659 to 
324 772)
–76% 
(–79 to 
–61)
Deaths 1 
(1 to 1)
0 
(0 to 0)
–74% 
(–76 to 
–69)
4 937 
(4 360 to 
5 147)
2 033 
(1 947 to 
2 224)
–59% 
(–61 to 
–51)
2 
(2 to 3)
1 
(1 to 1)
–75% 
(–78 to 
–60)
16 633 
(11 721 to 
18 979)
5 483 
(5 253 to 
6 125)
–67% 
(–71 to 
–50)
Prevalence 67 
(59 to 76)
33 
(28 to 39)
–51% 
(–54 to 
–47)
336 120 
(292 854 to 
384 061)
183 151 
(153 769 to 
216 836)
–46% 
(–50 to 
–41)
98 
(85 to 112)
53 
(45 to 62)
–46% 
(–49 to 
–42)
857 183 
(742 594 to 
983 424)
505 430 
(430 502 to 
591 790)
–41% 
(–45 to 
–37)
YLDs 7 
(5 to 9)
3 
(2 to 5)
–49% 
(–52 to 
–46)
31 197 
(21 873 to 
41 791)
17 079 
(12 032 to 
22 999)
–45% 
(–49 to 
–42)
9 
(6 to 12)
5 
(4 to 7)
–44% 
(–46 to 
–41)
76 367 
(53 464 to 
102 765)
45 301 
(31 738 to 
60 745)
–41% 
(–43 to 
–38)
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Age-
standardised 
rate, 1990
Age-
standardised 
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Change 
from 1990 
to 
 2017
Total, 1990 Total, 2017 Change 
from 
1990 to 
 2017
Age-
standardised 
rate, 1990
Age-
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rate, 2017
Change 
from 1990 
to 
 2017
Total, 1990 Total, 2017 Change 
from 
1990 to 
 2017
(Continued from previous page)
YLLs 69 
(65 to 75)
16 
(15 to 20)
–76% 
(–79 to 
–71)
247 423 
(231 164 to 
263 632)
67 471 
(64 007 to 
80 231)
–73% 
(–75 to 
–67)
163 
(107 to 193)
33 
(31 to 39)
–80% 
(–83 to 
–66)
1 106 091 
(733 867 to 
1 300 227)
243 313 
(230 129 to 
280 048)
–78% 
(–81 to 
–64)
Encephalitis
DALYs 20 
(14 to 21)
11 
(10 to 12)
–44% 
(–50 to 
–16)
81 788 
(62 092 to 
87 719)
57 720 
(50 302 to 
63 183)
–29% 
(–36 to 
–6)
42 
(38 to 48)
34 
(30 to 38)
–19% 
(–34 to –4)
321 230 
(291 041 to 
359 673)
270 736 
(236 953 to 
292 768)
–16% 
(–29 to –4)
Deaths 0 
(0 to 0)
0 
(0 to 0)
–30% 
(–36 to –9)
1 581 
(1 338 to 
1 648)
1 729 
(1 437 to 
1 829)
9% 
(1 to 24)
1 
(1 to 1)
1 
(0 to 1)
–11% 
(–24 to –2)
5 433 
(4 981 to 
5 885)
5 953 
(4 931 to 
6 266)
10% 
(–5 to 17)
Prevalence 26 
(14 to 41)
22 
(12 to 35)
–16% 
(–18 to 
–15)
141 844 
(76 154 to 
230 446)
142 435 
(74 374 to 
234 773)
0% 
(–2 to 3)
34 
(19 to 53)
29 
(17 to 46)
–14% 
(–15 to 
–13)
311 615 
(175 514 to 
494 479)
315 202 
(173 810 to 
507 091)
1% 
(–1 to 3)
YLDs 2 
(1 to 3)
2 
(1 to 2)
–18% 
(–20 to 
–17)
9 989 
(6 836 to 
13 303)
9 372 
(6 386 to 
12 593)
–6% 
(–8 to –4)
3 
(2 to 4)
2 
(2 to 3)
–15% 
(–17 to 
–14)
23 932 
(16 651 to 
31 792)
22 773 
(15 651 to 
30 309)
–5% 
(–7 to –3)
YLLs 18 
(12 to 19)
10 
(8 to 11)
–47% 
(–53 to 
–15)
71 799 
(52 152 to 
76 731)
48 348 
(41 387 to 
51 476)
–33% 
(–39 to 
–6)
40 
(36 to 46)
32 
(28 to 36)
–19% 
(–35 to –4)
297 298 
(266 649 to 
334 872)
247 963 
(214 185 to 
269 172)
–17% 
(–30 to –4)
Tetanus
DALYs 1 
(1 to 1)
0 
(0 to 0)
–90% 
(–92 to 
–88)
4809 
(3793 to 
5134)
649 
(558 to 755)
–86% 
(–88 to 
–84)
11 
(4 to 26)
0 
(0 to 0)
–98% 
(–99 to 
–95)
69 067 
(28 864 to 
158 779)
2127 
(1 860 to 
2 770)
–97% 
(–99 to 
–93)
Deaths 0 
(0 to 0)
0 
(0 to 0)
–90% 
(–91 to 
–88)
240 
(197 to 256)
39 
(33 to 46)
–84% 
(–86 to 
–81)
0 
(0 to 0)
0 
(0 to 0)
–96% 
(–98 to 
–92)
1 066 
(612 to 
2 088)
82 
(72 to 100)
–92% 
(–96 to 
–87)
Prevalence 0 
(0 to 0)
0 
(0 to 0)
–88% 
(–90 to 
–85)
26 
(20 to 30)
4 
(3 to 5)
–83% 
(–85 to 
–80)
0 
(0 to 0)
0 
(0 to 0)
–33% 
(–55 to 
–11)
214 
(166 to 296)
160 
(133 to 187)
–25% 
(–46 to –7)
YLDs 0 
(0 to 0)
0 
(0 to 0)
–90% 
(–91 to 
–88)
3 
(2 to 5)
1 
(0 to 1)
–85% 
(–87 to 
–82)
0 
(0 to 0)
0 
(0 to 0)
–77% 
(–88 to 
–58)
15 
(8 to 28)
4 
(3 to 7)
–72% 
(–84 to 
–54)
YLLs 1 
(1 to 1)
0 
(0 to 0)
–90% 
(–92 to 
–88)
4806 
(3790 to 
5131)
649 
(558 to 754)
–86% 
(–88 to 
–84)
11 
(4 to 26)
0 
(0 to 0)
–98% 
(–99 to 
–95)
69 051 
(28 852 to 
158 748)
2 122 
(1 856 to 
2 765)
–97% 
(–99 to 
–93)
Epilepsy
DALYs 149 
(105 to 208)
140 
(90 to 211)
–7% 
(–30 to 
24)
735 793 
(514 448 to 
1 023 814)
781 549 
(512 458 to 
1 168 936)
6% 
(–20 to 
41)
179 
(137 to 235)
158 
(113 to 220)
–12% 
(–29 to 9)
1 507 756 
(1 145 663 to 
1 988 615)
1 479 134 
(1 063 428 to 
2 050 641)
–2% 
(–21 to 21)
Deaths 1 
(1 to 1)
1 
(1 to 1)
3% 
(–28 to 11)
6223 
(6106 to 
6782)
9 526 
(7286 to 
10 097)
53% 
(3 to 64)
1 
(1 to 2)
1 
(1 to 1)
–8% 
(–26 to 8)
12 528 
(11 675 to 
13 504)
15 370 
(12 663 to 
16 443)
23% 
(–4 to 38)
Prevalence 358 
(241 to 470)
399 
(266 to 529)
11% 
(–19 to 
50)
1 794 858 
(1 198 133 to 
2 356 841)
2 244 668 
(1 496 976 to 
2 977 225)
25% 
(–9 to 69)
352 
(259 to 453)
385 
(280 to 497)
9% 
(–15 to 35)
3 082 147 
(2 254 550 to 
3 960 937)
3 742 828 
(2 718 716 to 
4 823 770)
21% 
(–6 to 50)
YLDs 98 
(53 to 156)
96 
(48 to 166)
–2% 
(–37 to 
49)
482 243 
(264 069 to 
770 314)
523 003 
(259 741 to 
908 273)
8% 
(–31 to 
64)
104 
(63 to 159)
100 
(57 to 160)
–3% 
(–32 to 30)
894 217 
(541 420 to 
1 373 670)
942 629 
(528 597 to 
1 512 164)
5% 
(–25 to 44)
YLLs 52 
(51 to 59)
44 
(40 to 47)
–15% 
(–40 to –8)
253 550 
(247 508 to 
285 858)
258 546 
(219 592 to 
274 228)
2% 
(–30 to 
10)
75 
(65 to 84)
58 
(53 to 64)
–23% 
(–35 to –4)
613 539 
(549 291 to 
680 608)
536 505 
(490 237 to 
585 052)
–13% 
(–28 to 5)
Migraine
DALYs 763 
(491 to 
1106)
770 
(495 to 
1 115)
1% 
(0 to 2)
3 947 343 
(2 552 335 to 
5 707 835)
4 231 019 
(2 740 462 to 
6 048 715)
7% 
(5 to 9)
737 
(475 to 1059)
735 
(473 to 
1056)
0% 
(–1 to 1)
6 702 168 
(4 320 439 to 
9 679 278)
7 401 471 
(4 810 162 to 
10 539 348)
10% 
(9 to 12)
(Table 2 continues on next page)
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The high proportion of DALYs and deaths attributable 
to neurological disorders can be explained in part by 
the long life expectancy in Europe and, despite an 
overall decrease in age­standardised rates, by the 
increasing incidence and the increasingly long duration 
of ageing­related diseases.10 Population growth 
could also be implicated. The total population of 
Europe was 721 million in 1990 and rose to 916 million 
by 2016.11
While the substantial sex differences observed in the 
burden of neurological disorders reflect the differing 
distribution of each clinical condition in men and 
women, the increasing number of DALYs attributable to 
the most common clinical conditions with age is most 
likely linked with the ageing of the European population. 
The peak of DALYs observed in the oldest age groups 
reflects the predominance of ageing­related diseases in 
these older age groups. The predominance of dementia 
in the oldest groups in the EU28 and in western Europe 
can be similarly explained.
Stroke, migraine, and dementia were the major con­
tributors to the overall burden of neurological disorders 
when comparing the EU28, western, central, and eastern 
Europe, but with different numbers according to age. 
Whereas in western Europe dementia and stroke were 
the largest contributors to the burden of neurological 
disorders after age 70 years in both sexes, stroke was the 
strongest contributor between age 40 years and 89 years 
in central Europe and between age 50 years and 89 years 
in eastern Europe. National and regional differences in 
population age structure (for dementia), implementation 
of pre ventive and therapeutic measures (for stroke), and 
attention to diseases and access to health­care facilities 
are possible explanations.
This study has shown differences among WHO 
subregions in the proportion of DALYs, deaths, and 
EU28 WHO European region
Age-
standardised 
rate, 1990
Age-
standardised 
rate, 2017
Change 
from 1990 
to 
 2017
Total, 1990 Total, 2017 Change 
from 
1990 to 
 2017
Age-
standardised 
rate, 1990
Age-
standardised 
rate, 2017
Change 
from 1990 
to 
 2017
Total, 1990 Total, 2017 Change 
from 
1990 to 
 2017
(Continued from previous page)
Prevalence 20 543 
(19 061 to 
22 105)
20 646 
(19 234 to 
22 225)
0% 
(0 to 1)
105 746 319 
(98 488 927 to 
113 530 086)
112 207 672 
(104 739 016 
to 
119 973 469)
6% 
(4 to 8)
19 697 
(18 304 to 
21 171)
19 650 
(18 270 to 
21 082)
0% 
(–1 to 1)
178 317 032 
(166 023 492 to 
191 281 010)
195 794 407 
(182 677 431 to 
209 186 190)
10% 
(8 to 11)
YLDs 763 
(491 to 1 106)
770 
(495 to 1 115)
1% 
(0 to 2)
3 947 343 
(2 552 335 to 
5 707 835)
4 231 019 
(2 740 462 to 
6 048 715)
7% 
(5 to 9)
737 
(475 to 1 059)
735 
(473 to 1 056)
0% 
(–1 to 1)
6 702 168 
(4 320 439 to 
9 679 278)
7 401 471 
(4 810 162 to 
10 539 348)
10% 
(9 to 12)
Tension-type headache
DALYs 102 
(58 to 160)
101 
(57 to 159)
0% 
(–2 to 1)
542 038 
(309 633 to 
850 297)
600 667 
(343 433 to 
936 239)
11% 
(8 to 14)
113 
(64 to 176)
110 
(63 to 173)
–2% 
(–3 to –1)
1 043 015 
(596 692 to 
1 625 120)
1 163 732 
(664 951 to 
1 799 904)
12% 
(9 to 14)
Prevalence 31 256 
(28 329 to 
34 499)
30 871 
(28 014 to 
33 930)
–1% 
(–2 to 0)
162 144 987 
(147 265 221 to 
178 088 317)
173 696 347 
(158 485 543 
to 
190 762 959)
7% 
(5 to 10)
31 858 
(28 899 to 
35 154)
31 022 
(28 086 to 
34 097)
–3% 
(–3 to –2)
287 861 348 
(261 220 814 to 
316 795 771)
309 890 284 
(281 758 135 to 
340 323 834)
8% 
(6 to 10)
YLDs 102 
(58 to 160)
101 
(57 to 159)
0% 
(–2 to 1)
542 038 
(309 633 to 
850 297)
600 667 
(343 433 to 
936 239)
11% 
(8 to 14)
113 
(64 to 176)
110 
(63 to 173)
–2% 
(–3 to –1)
1 043 015 
(596 692 to 
1 625 120)
1 163 732 
(664 951 to 
1 799 904)
12% 
(9 to 14)
Other neurological disorders
DALYs 66 
(57 to 76)
65 
(54 to 79)
–1% 
(–16 to 16)
313 735 
(277 741 to 
360 083)
363 480 
(314 552 to 
426 877)
16% 
(3 to 30)
64 
(55 to 75)
63 
(54 to 76)
–1% 
(–14 to 15)
531 078 
(460 688 to 
617 442)
599 059 
(517 397 to 
698 284)
13% 
(0 to 28)
Deaths 1 
(1 to 1)
1 
(1 to 1)
–2% 
(–11 to 6)
7205 
(6931 to 7450)
10 303 
(9219 to 
10 814)
43% 
(26 to 52)
1 
(1 to 1)
1 
(1 to 1)
1% 
(–8 to 10)
9941 
(9424 to 
10 402)
14 052 
(12 762 to 
14 637)
41% 
(26 to 52)
Prevalence 0 
(0 to 1)
0 
(0 to 1)
7% 
(4 to 11)
2067 
(1372 to 2855)
2 613 
(1736 to 3517)
26% 
(20 to 34)
0 
(0 to 1)
0 
(0 to 1)
4% 
(2 to 6)
3674 
(2440 to 5020)
4364 
(2939 to 5868)
19% 
(13 to 26)
YLDs 18 
(11 to 28)
23 
(13 to 37)
28% 
(–8 to 76)
84 916 
(54 641 to 
126 893)
112 433 
(68 271 to 
174 266)
32% 
(0 to 76)
19 
(12 to 28)
24 
(15 to 36)
24% 
(–6 to 61)
159 965 
(104 111 to 
235 740)
206 737 
(130 672 to 
304 277)
29% 
(1 to 63)
YLLs 48 
(45 to 52)
42 
(39 to 44)
–12% 
(–24 to –3)
228 818 
(218 306 to 
242 385)
251 047 
(232 719 to 
264 643)
10% 
(–2 to 20)
45 
(39 to 50)
40 
(37 to 42)
–12% 
(–24 to 3)
371 114 
(333 652 to 
403 551)
392 321 
(369 776 to 
410 145)
6% 
(–6 to 20)
Data are n (95% UI) or % (95% UI). DALYs=disability-adjusted life-years. EU=the 27 EU countries plus the UK. YLDs=years lived with disability. YLLs=years of life lost. UI=uncertainty interval.
Table 2: DALYs, death, prevalence, YLDs, YLLs, and rates of neurological disorders by category in the EU28 and WHO European region, with changes from 1990 to 2017
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prevalence attributable to the commonest neurological 
disorders. Stroke was the largest contributor to the total 
DALYs in eastern Europe, followed by central and 
western Europe, whereas dementia showed the opposite 
gradient.
Stroke was the leading source of burden attributable to 
neurological disorders in the EU28 and the WHO 
European region. The age­standardised DALY rate for 
stroke was significantly higher in high­middle SDI than 
in high­SDI countries. Stroke is the overall leading 
contributor of DALYs and deaths worldwide.12 However, 
the declining all­age and age­standardised DALYs 
attributable to stroke is an important finding. As the 
prevalence of stroke showed a substantial increase, 
possibly due to the ageing of the society and the 
increasing detection of less severe cases, we found a 
corresponding decrease in DALYs, both absolute and 
relative. Preventive medicine and lifestyle changes are 
the most likely explanations and underscore the effects 
of increasing control of preventable risk factors (blood 
pressure control and smoking cessation) affecting 
mainly the prevalence. Previous reports from the GBD 
collaborators showed that more than 90% of the stroke 
burden was attributable to modifiable risk factors.13–16 
Stroke unit care and thrombolysis have been proposed to 
have a role in ameliorating the outcome of ischaemic 
stroke17 and can explain the significant reduction in 
deaths and DALYs per patient. In the USA, the rate of use 
of r­TPA began to increase in 2001 and progressed 
steadily in the subsequent years.18 Similar trends are 
most likely present in Europe.
The increasing burden of Alzheimer’s disease and 
other dementias observed since 1990 is in line with 
increases in life expectancy, with burden increasing most 
rapidly in the population aged 60 years or older due to 
increasing longevity and declining birth rates.19
Another notable disease with a large increase in 
prevalence and DALYs was Parkinson’s disease. The global 
burden of Parkinson’s disease more than doubled during 
the study period.20 The growth of the burden of Parkinson’s 
disease surpassed that of Alzheimer’s disease and other 
dementias. This increase has been attributed to the ageing 
of the European population, the reduction of rural 
populations, occupational exposures, and the declining 
smoking rates.21,22 Although increased attention towards 
the disease might partially explain the increasing incidence 
observed, Parkinson’s disease is still underdiagnosed, as 
shown in the USA23 and by an online European survey 
that found that 40% of respondents had never seen a 
Parkinson’s disease specialist.24,25
A substantial increase in all the measures of burden 
has been observed in Europe for motor neuron disease, 
another ageing­related disease. However, contrary to the 
other neurodegenerative diseases, we found a parallel 
increase of age­standardised rates, which can be 
explained by an increasing diagnostic accuracy rather 
than a true increase of the incidence of the disease.
Primary headache (migraine and tension­type head ache) 
was the most prevalent neurological disorder and the 
second highest source of burden both in high­SDI and in 
high­middle SDI countries. Headache is a major public 
health concern worldwide. Based on the results of the 
GBD Study 2016,26 almost 3 billion individuals were 
estimated to have repeated migraine or tension­type 
headache attacks, accounting for a total of 52·3 million 
YLDs. In the WHO European region, migraine and 
High-SDI countries High-middle SDI countries
1990 2017 Change 1990 2017 Change
Stroke 1286 (1228 to 1341) 650 (597 to 703) –49% (–52 to –47) 3196 (3097 to 3294) 1998 (1900 to 2104) –37% (–40 to –35)
Alzheimer’s disease 
and other dementias
430 (403 to 458) 399 (373 to 426) –7% (–9 to –5) 466 (436 to 497) 439 (410 to 472) –6% (–8 to –3)
Parkinson’s disease 63 (58 to 74) 67 (59 to 73) 6% (–16 to 11) 78 (72 to 86) 74 (68 to 83) –4% (–10 to 0)
Motor neuron disease 28 (27 to 29) 31 (30 to 32) 11% (6 to 16) 8 (7 to 12) 10 (9 to 11) 17% (–22 to 43)
Multiple Sclerosis 33 (28 to 28) 34 (29 to 40) 6% (–12 to 10) 14 (12 to 16) 11 (10 to 13) –21% (–31 to –1)
Brain and nervous 
system cancer
125 (112 to 139) 114 (99 to 124) –9% (–25 to 3) 148 (113 to 169) 132 (117 to 147) –11% (–22 to 16)
Meningitis 62 (58 to 66) 19 (17 to 22) –70% (–72 to –63) 201 (144 to 227) 46 (40 to 49) –77% (–80 to –71)
Encephalitis 14 (13 to 15) 10 (9 to 12) –27% (–34 to –12) 54 (46 to 64) 32 (28 to 38) –41% (–54 to –16)
Tetanus 1 (1 to 1) 0 (0 to 0) –89% (–90 to –86) 43 (33 to 54) 2 (1 to 3) –95% (–97 to –91)
Epilepsy 125 (88 to 171) 118 (77 to 173) –6% (–23 to 14) 175 (138 to 223) 127 (91 to 177) –27% (–42 to –9)
Migraine 676 (433 to 975) 674 (431 to 970) 0% (–1 to –1) 550 (350 to 800) 552 (351 to 804) 0% (–1 to 2)
Tension-type 
headache
93 (53 to 147) 93 (53 to 148) 0% (–1 to 1) 97 (55 to 151) 92 (52 to 145) –5% (–6 to –3)
Other neurological 
disorders
61 (54 to 70) 61 (52 to 72) 0% (–10 to –10) 46 (37 to 56) 45 (37 to 57) –2% (–18 to 21)
Data are n (95% UI) or % (95% UI). DALY=disability-adjusted life-year. EU28=the 27 EU countries plus the UK. SDI=socio-demographic index. UI=uncertainty interval.
Table 3: Age-standardised DALY rates by SDI in the EU28 and WHO European region from 1990 to 2017
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tension­type headache were the second most common 
source of burden attributable to neurological disorders 
(the third in the EU28). In this study, headache was in line 
with the worldwide burden of the disease and, by 
definition, accounted for a substantial health loss in terms 
of YLDs, with premature mortality virtually absent. Despite 
the abundance of symptomatic drugs available to treat 
headache, we found a modest increase in the absolute 
measures of burden of headache, suggesting that 
interventions should be directed towards increasing public 
knowledge of and decreasing exposure to modifiable risk 
factors, such as obesity, smoking, air pollution, low 
physical activity, blood pressure, and stress.26
Contrary to other neurological disorders and in spite of a 
slight increase in prevalence and deaths, epilepsy showed 
a reduction in all­age and age­standardised DALYs in 
Europe. The increasing number of deaths might be due to 
the ageing of the European population. This finding is not 
unexpected because epilepsy incidence is age related, with 
a first peak in the young but a steady increase in the older 
population and thereby an increase of mortality in an 
ageing society.27 The decreasing burden might be instead a 
reflection of improved management. The differences 
between high­SDI countries (showing a slight increase) 
and high­middle­SDI countries (showing a significant 
decrease) can be explained by the contrasting effects of 
ageing and quality of care, with a negative balance in 
countries with top economies (where the management of 
epilepsy could not further improve despite the increasing 
number of affected individuals) and a positive balance in 
growing economies (where the quality of care might be 
rapidly improving).
Multiple sclerosis is less frequent than other neurological 
disorders. The increasing prevalence, and the consequent 
burden, when comparing the first and the last year of the 
study period, could be due to the changing classifications 
of the disease. The disease can now be diagnosed earlier 
than was possible at the start of the study. Patients with 
clinically isolated syndromes showing one attack and 
evidence of two or more T2 or gadolinium­enhancing 
lesions have been included since 2010.28 Therefore, the 
incidence of the disease might not be truly increasing, 
but the expansion of the diagnostic boundaries might 
be a source of increasing burden and, consequently, of 
expenditures for the propensity of the caring physicians to 
anticipate the onset of treatment with disease­modifying 
drugs in the attempt to improve the disease course.29
In line with the global decrease of absolute numbers 
and age­standardised rates,30 CNS infections and tetanus 
showed a significant decrease in the EU28 and the WHO 
European region. The increase in prevalence and YLDs 
and, to a lesser extent, the increase of deaths attributable 
to brain tumours can be explained by better diagnostic 
ascertainment; the role of environmental risk factors is 
controversial.31,32
All the other neurological disorders accounted for a low 
proportion of the overall burden, due to low prevalence 
or a less remarkable effect on life expectancy or functional 
abilities.
The standardised DALY rates for all neurological 
diseases varied across countries but, with few exceptions, 
we found an overall decrease, mostly driven by a 
reduction in premature mortality. Given the predominant 
role of stroke in terms of attributable proportion, we 
infer that the decrease in DALYs overall is in large part 
explained by the improved prevention of stroke deaths.
The major strength of the study is the collection of 
epidemiological data worldwide using the same metho­
dology and modelling measures. This methodology 
allowed us to document major differences between 
the EU28 and the WHO European region and within 
European countries in the burden of neurological 
disorders. Our study was able to highlight geographical 
trends in the burden of stroke within Europe and suggests 
that prevention and treatment are still deficient in several 
European countries. These results can be helpful for local 
authorities to address the burden of preventable and 
treatable neurological disorders. Other strengths are the 
continuous refinement of the available data, adding new 
original sources and the use of more sophisticated 
statistical methods when available, which allowed us to 
compare the European situation with the spectrum of the 
global situation.
This study also has limitations. First, because original 
epidemiological data were not available for all countries, 
Bayesian statistical models were used to estimate deaths 
and disease prevalence for countries where information 
was missing. For this reason, the inclusion in future of 
new primary data from countries with little data could 
lead to more precise estimates that might vary 
from current predicted values. Second, the disability 
weights used for the calculation of YLDs might not 
be uniform across populations and socio demographic 
strata. However, a systematic variation in disability 
weights across populations, or within the same popu­
lation as a function of education, was not detected by 
population surveys.7,33 Third, the 95% UIs are frequently 
wide, reflecting the low precision of the estimates 
and potentially limiting the ability to detect smaller 
differences across countries. Additional data on the 
proportions influencing the sequelae of neurological 
disorders might reduce uncertainties in future analyses. 
Fourth, neurological diseases can be correlated 
with other somatic and psychiatric comorbidities and 
injuries. Here, the correction for comorbidity was based 
on the assumption that diseases and their sequelae are 
independent. Future improvements of the GBD 
modelling should include dependent comorbidity. Fifth, 
disease rankings that are based on age­standardised 
rates can be influenced by the choice of the standard 
population. Sixth, the use of medical claims data could 
be biased because people who are not treated or are 
excluded from health insurance would not be counted. 
Seventh, the results reflect the study period and the 
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quality of the sources. Additionally, the variable quality 
and completeness of the information available can 
partly explain the differences found when comparing 
the different European countries. Eighth, the definition 
of causes of death reflects the quality and completeness 
of the sources. Finally, several highly prevalent 
neurological diseases are not yet included in the GBD 
database, such as sleep disorders,34 essential tremor,35 or 
restless legs syndrome.36
This study has shown the huge burden of neurological 
disorders in Europe. The numbers of citizens affected and 
the numbers of neurological DALYs and deaths call for 
action regarding this disease group. The major challenge 
for all countries is the increasing number of neurological 
diseases even if the DALYs per patient are decreasing for 
some conditions. Despite many similarities, the most 
prevalent diseases differ considerably in different regions 
or even countries and thus policy and actions needed might 
differ. Strategic planning in European countries might use 
this information to customise plans to efficiently deal with 
this burden. However, to improve the precision of our 
estimates, new studies are awaited to provide original data 
in countries where the information regarding the incidence, 
prevalence, and mortality of the target diseases is not yet 
available. The inclusion of these data in our models can 
correct the present findings and provide a more accurate 
estimate of the burden of neurological diseases and trends.
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